공지 • Sep 09
Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in funding Optimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid. Reported Earnings • Jul 31
First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025) First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025). New Risk • Jul 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k). Reported Earnings • Jun 30
Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024) Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024). Reported Earnings • Jan 31
Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024) Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024). Reported Earnings • Nov 01
Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024) Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024). Reported Earnings • Aug 01
First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024) First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024). 공지 • Jul 05
Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in funding Optimind Pharma Corp. announced a private placement to issue 10,000,000 common shares at a price of CAD 0.05 per share for gross proceeds of up to CAD 500,000 on July 3, 2024. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities. Reported Earnings • Jul 01
Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023) Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023). Board Change • Jan 26
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jan 12
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 11
Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 3Q 2023) Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.01 loss in 3Q 2023). Revenue: CA$26.7k (down 38% from 3Q 2023). Net loss: CA$104.4k (loss narrowed 89% from 3Q 2023). 공지 • Jan 10
Optimind Pharma Corp. Announces Executive Changes Optimind Pharma Corp. announced that David Goodman, a member of the Company's Board of Directors, assumes the mantle of Chief Executive Officer ("CEO") with a forward-looking vision for Optimind's continued growth and innovation. Former CEO and Director, Tom Sipos, has gracefully stepped down due to personal reasons. The Company expresses gratitude to Mr. Sipos for his valuable contributions and extends best wishes for his future endeavors. Reported Earnings • Nov 01
Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.01 loss in 2Q 2023) Second quarter 2024 results: CA$0.002 loss per share (improved from CA$0.01 loss in 2Q 2023). Revenue: CA$27.4k (down 36% from 2Q 2023). Net loss: CA$183.5k (loss narrowed 81% from 2Q 2023). Reported Earnings • Jul 30
First quarter 2024 earnings released First quarter 2024 results: CA$0.004 loss per share. Net loss: CA$403.7k (flat on 1Q 2023). 공지 • May 19
Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023 Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023. 공지 • Sep 21
Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million. Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million on September 20, 2022. The acquisition was completed pursuant to an asset purchase agreement (the "APA") with Beatrice Society. Pursuant to the APA, the Company has issued a total of 22,500,000 common shares to the vendor which are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property.
Optimind Pharma Corp. (CNSX:OMND) completed the acquisition of MindSetting Inc. from Beatrice Society Inc. on September 20, 2022. 
